Organovo Stock Price, News & Analysis (NASDAQ:ONVO)

$1.41 0.04 (2.92 %)
(As of 01/21/2018 03:51 AM ET)
Previous Close$1.41
Today's Range$1.34 - $1.41
52-Week Range$1.32 - $3.85
Volume1.42 million shs
Average Volume1.48 million shs
Market Capitalization$150.76 million
P/E Ratio-3.71
Dividend YieldN/A
Beta3.08

About Organovo (NASDAQ:ONVO)

Organovo logoOrganovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ONVO
CUSIPN/A
Phone+1-858-5509994

Debt

Debt-to-Equity RatioN/A
Current Ratio12.95%
Quick Ratio12.83%

Price-To-Earnings

Trailing P/E Ratio-3.71052631578947
Forward P/E Ratio-3.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.23 million
Price / Sales35.64
Cash FlowN/A
Price / CashN/A
Book Value$0.60 per share
Price / Book2.35

Profitability

Trailing EPS($0.38)
Net Income$-38,440,000.00
Net Margins-923.89%
Return on Equity-65.63%
Return on Assets-60.32%

Miscellaneous

Employees113
Outstanding Shares106,920,000

Organovo (NASDAQ:ONVO) Frequently Asked Questions

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) announced its quarterly earnings results on Thursday, November, 9th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The medical research company earned $1.36 million during the quarter, compared to the consensus estimate of $1.38 million. Organovo had a negative net margin of 923.89% and a negative return on equity of 65.63%. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. View Organovo's Earnings History.

When will Organovo make its next earnings announcement?

Organovo is scheduled to release their next quarterly earnings announcement on Thursday, February, 8th 2018. View Earnings Estimates for Organovo.

Where is Organovo's stock going? Where will Organovo's stock price be in 2018?

5 Wall Street analysts have issued 1 year price targets for Organovo's stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Organovo's stock price to reach $3.94 in the next twelve months. View Analyst Ratings for Organovo.

What are Wall Street analysts saying about Organovo stock?

Here are some recent quotes from research analysts about Organovo stock:

  • 1. According to Zacks Investment Research, "Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. " (12/27/2017)
  • 2. BTIG Research analysts commented, "Reset Delays Ramp; Trimming PT From $5 to $3 We are updating our model and price target to reflect Q3 results and a slower than anticipated revenue ramp as a result of the company’s strategy focus toward fast-growing, higher margin compound screening and disease modeling. We continue to feel ONVO is a long-term investment with sizable market opportunities ($3B+) but as the technology is quite new, predicting the rate at which pharma and research partners will adopt this new technology can be tricky. As our model now incorporates more risk in the near-term given the change in strategy, our revised DCF yields a $3 PT, down from $5 previously. We maintain our Buy rating.   Commentary on revenue mix is encouraging. In the call, management noted a 60%/40% split between repeat and new orders in the first half of the fiscal year, consistent with the mix seen in Fiscal 2017. Additionally, average revenue per order also continues to rise, driven by the aforementioned shift to higher value disease modeling. Finally, management also suggested the potential for a few of its clients to shift from single project to annual revenue commitment contracts over the next couple of quarters.   Valuation: Our price target is $3, based on a DCF analysis that assumes a WACC of 15% and a LT growth rate of 3%. Risks follow on page 6." (11/16/2017)

Who are some of Organovo's key competitors?

Who are Organovo's key executives?

Organovo's management team includes the folowing people:

  • Taylor J. Crouch, President, Chief Executive Officer (Age 57)
  • Eric Michael David M.D. J.D., Executive Vice President - Pre-Clinical Development, Chief Strategy Officer (Age 48)
  • Sharon Collins Presnell Ph.D., Chief Scientific Officer (Age 47)
  • Jennifer Kinsbruner Bush, Compliance Officer, General Counsel, Corporate Secretary (Age 41)
  • Paul Gallant, General Manager (Age 51)
  • Richard Maroun, Director
  • Robert F Baltera Jr., Lead Independent Director (Age 51)
  • James T. Glover, Independent Director (Age 66)
  • Richard A. Heyman Ph.D., Independent Director (Age 59)
  • Tamar D. Howson, Independent Director (Age 68)

How do I buy Organovo stock?

Shares of Organovo can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Organovo's stock price today?

One share of Organovo stock can currently be purchased for approximately $1.41.

How big of a company is Organovo?

Organovo has a market capitalization of $150.76 million and generates $4.23 million in revenue each year. The medical research company earns $-38,440,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Organovo employs 113 workers across the globe.

How can I contact Organovo?

Organovo's mailing address is 6275 Nancy Ridge Drive Suite 110, SAN DIEGO, CA 92121, United States. The medical research company can be reached via phone at +1-858-5509994 or via email at [email protected]


MarketBeat Community Rating for Organovo (ONVO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Organovo (NASDAQ:ONVO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.603.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.94$3.94$6.94$6.94
Price Target Upside: 183.27% upside183.27% upside247.74% upside157.90% upside

Organovo (NASDAQ:ONVO) Consensus Price Target History

Price Target History for Organovo (NASDAQ:ONVO)

Organovo (NASDAQ:ONVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017BTIG ResearchReiterated RatingBuy$3.00N/AView Rating Details
11/10/2017CitigroupDowngradeMarket PerformN/AView Rating Details
11/10/2017Raymond James FinancialDowngradeOutperform -> Market Perform$5.00N/AView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$4.00HighView Rating Details
6/12/2017Evercore ISILower Price TargetOutperform$4.00 -> $3.75N/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Organovo (NASDAQ:ONVO) Earnings History and Estimates Chart

Earnings by Quarter for Organovo (NASDAQ:ONVO)

Organovo (NASDAQ ONVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018N/AView Earnings Details
11/9/2017Q2 2018($0.10)($0.09)$1.38 million$1.36 millionViewN/AView Earnings Details
8/9/2017Q1 2018($0.10)($0.10)$0.92 million$0.99 millionViewListenView Earnings Details
6/7/2017Q4 2017($0.11)($0.10)$0.76 million$0.80 millionViewListenView Earnings Details
2/9/2017Q3 2017($0.10)($0.09)$1.40 million$1.15 millionViewListenView Earnings Details
11/3/2016Q217($0.11)($0.10)$0.50 million$1.38 millionViewListenView Earnings Details
8/4/2016Q1($0.10)($0.09)$0.30 million$0.89 millionViewListenView Earnings Details
6/9/2016Q4($0.11)($0.09)$0.10 million$0.55 millionViewListenView Earnings Details
2/8/2016Q3 2016($0.11)($0.11)ViewN/AView Earnings Details
11/9/2015Q2 2016($0.10)($0.12)ViewN/AView Earnings Details
8/10/2015Q1 2016($0.10)($0.10)ViewN/AView Earnings Details
2/9/2015Q3 2015($0.09)ViewN/AView Earnings Details
11/10/2014Q2 2015($0.11)ViewN/AView Earnings Details
8/12/2014Q1 2015($0.08)ViewN/AView Earnings Details
6/12/2014Q4 2014($0.11)ViewN/AView Earnings Details
2/7/2014Q3 2014($0.06)ViewN/AView Earnings Details
11/12/2013Q2 2014($0.14)ViewN/AView Earnings Details
8/12/2013Q1 2014($0.06)($0.06)ViewN/AView Earnings Details
5/28/2013Q4 2013($0.13)ViewN/AView Earnings Details
3/18/2013Q3 2013($0.05)($0.08)ViewN/AView Earnings Details
11/16/2012Q2 2013$0.70$0.69ViewN/AView Earnings Details
8/15/2012Q1 2013($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Organovo (NASDAQ:ONVO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.10)
2019 EPS Consensus Estimate: ($0.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.10)($0.10)($0.10)
Q1 20191($0.09)($0.09)($0.09)
Q2 20191($0.09)($0.09)($0.09)
Q3 20191($0.07)($0.07)($0.07)
Q4 20191($0.07)($0.07)($0.07)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Organovo (NASDAQ:ONVO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Organovo (NASDAQ ONVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 25.78%
Insider Trades by Quarter for Organovo (NASDAQ:ONVO)
Insider Trades by Quarter for Organovo (NASDAQ:ONVO)

Organovo (NASDAQ ONVO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2017Keith MurphyCEOSell25,000$3.68$92,000.00View SEC Filing  
1/24/2017Keith MurphyCEOSell25,000$3.51$87,750.006,059,015View SEC Filing  
12/14/2016Keith MurphyCEOSell50,000$3.72$186,000.00View SEC Filing  
8/5/2016Eric DavidEVPSell20,000$4.55$91,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Organovo (NASDAQ ONVO) News Headlines

Source:
DateHeadline
Organovo Holdings Inc (ONVO) Receives Consensus Rating of "Hold" from BrokeragesOrganovo Holdings Inc (ONVO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 16 at 1:38 AM
Organovo Holdings Inc (ONVO) Expected to Post Quarterly Sales of $1.23 MillionOrganovo Holdings Inc (ONVO) Expected to Post Quarterly Sales of $1.23 Million
www.americanbankingnews.com - January 6 at 2:16 AM
Organovo (ONVO) Stock Rating Lowered by Zacks Investment ResearchOrganovo (ONVO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - December 28 at 11:42 PM
ETFs with exposure to Organovo Holdings, Inc. : December 28, 2017ETFs with exposure to Organovo Holdings, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:54 PM
Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q2, 2018 By the Numbers : December 27, 2017Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q2, 2018 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:06 PM
Organovo (ONVO) Granted Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin DeficiencyOrganovo (ONVO) Granted Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
www.streetinsider.com - December 26 at 10:11 AM
32 Stocks Moving In Tuesdays Pre-Market Session32 Stocks Moving In Tuesday's Pre-Market Session
feeds.benzinga.com - December 26 at 9:30 AM
Organovo Holdings Inc (ONVO) Receives Consensus Recommendation of "Hold" from AnalystsOrganovo Holdings Inc (ONVO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 22 at 2:06 AM
$1.23 Million in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter$1.23 Million in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter
www.americanbankingnews.com - December 21 at 10:54 AM
Zacks: Brokerages Expect Organovo Holdings Inc (ONVO) Will Announce Earnings of -$0.10 Per ShareZacks: Brokerages Expect Organovo Holdings Inc (ONVO) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 19 at 5:20 AM
ETFs with exposure to Organovo Holdings, Inc. : December 15, 2017ETFs with exposure to Organovo Holdings, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 4:47 PM
Where Will Organovo Holdings, Inc. Be in 5 Years?Where Will Organovo Holdings, Inc. Be in 5 Years?
www.fool.com - December 3 at 3:03 PM
Organovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by BrokeragesOrganovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
Zacks: Organovo Holdings, Inc. (ONVO) Receives Average Recommendation of "Buy" from BrokeragesZacks: Organovo Holdings, Inc. (ONVO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 19 at 1:16 PM
Organovo Holdings, Inc. (ONVO) Given "Buy" Rating at BTIG ResearchOrganovo Holdings, Inc. (ONVO) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - November 16 at 10:40 AM
Contrasting Organovo Holdings (ONVO) & Novelion Therapeutics (NVLN)Contrasting Organovo Holdings (ONVO) & Novelion Therapeutics (NVLN)
www.americanbankingnews.com - November 16 at 8:37 AM
 Organovo Holdings, Inc. (ONVO) Given $3.25 Consensus Target Price by Brokerages Organovo Holdings, Inc. (ONVO) Given $3.25 Consensus Target Price by Brokerages
www.americanbankingnews.com - November 15 at 5:06 AM
Zacks: Analysts Expect Organovo Holdings, Inc. (ONVO) Will Announce Quarterly Sales of $1.93 MillionZacks: Analysts Expect Organovo Holdings, Inc. (ONVO) Will Announce Quarterly Sales of $1.93 Million
www.americanbankingnews.com - November 14 at 6:04 AM
Organovo Holdings, Inc. (ONVO) Expected to Post Earnings of -$0.09 Per ShareOrganovo Holdings, Inc. (ONVO) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - November 12 at 5:42 PM
Organovo Holdings, Inc. (ONVO) Rating Lowered to Market Perform at Raymond James Financial, Inc.Organovo Holdings, Inc. (ONVO) Rating Lowered to Market Perform at Raymond James Financial, Inc.
www.americanbankingnews.com - November 12 at 11:16 AM
Citigroup Inc. Downgrades Organovo Holdings, Inc. (ONVO) to Market PerformCitigroup Inc. Downgrades Organovo Holdings, Inc. (ONVO) to Market Perform
www.americanbankingnews.com - November 10 at 2:48 PM
Organovo Holdings, Inc. (ONVO) Releases  Earnings Results, Beats Estimates By $0.01 EPSOrganovo Holdings, Inc. (ONVO) Releases Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 9 at 10:36 PM
Head-To-Head Comparison: Organovo Holdings (ONVO) and The CompetitionHead-To-Head Comparison: Organovo Holdings (ONVO) and The Competition
www.americanbankingnews.com - November 6 at 1:20 AM
Organovo Holdings (ONVO) vs. Its Rivals Head to Head ReviewOrganovo Holdings (ONVO) vs. Its Rivals Head to Head Review
www.americanbankingnews.com - November 5 at 1:20 PM
Organovo Holdings, Inc. (ONVO) Receives Consensus Recommendation of "Hold" from AnalystsOrganovo Holdings, Inc. (ONVO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 2 at 12:00 PM
Organovo Holdings, Inc. (ONVO) Set to Announce Earnings on ThursdayOrganovo Holdings, Inc. (ONVO) Set to Announce Earnings on Thursday
www.americanbankingnews.com - November 2 at 3:04 AM
ETFs with exposure to Organovo Holdings, Inc. : October 30, 2017ETFs with exposure to Organovo Holdings, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 7:29 AM
Organovo (ONVO) Reports New Preclinical Data on 3D Bioprinted ... - StreetInsider.comOrganovo (ONVO) Reports New Preclinical Data on 3D Bioprinted ... - StreetInsider.com
www.streetinsider.com - October 21 at 7:29 AM
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting® 2017 (AASLD)Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting® 2017 (AASLD)
finance.yahoo.com - October 21 at 7:29 AM
ETFs with exposure to Organovo Holdings, Inc. : October 20, 2017ETFs with exposure to Organovo Holdings, Inc. : October 20, 2017
finance.yahoo.com - October 21 at 7:29 AM
Organovo Announces Release Date for Fiscal Second-Quarter 2018 Financial ResultsOrganovo Announces Release Date for Fiscal Second-Quarter 2018 Financial Results
finance.yahoo.com - October 20 at 7:08 AM
Organovo Holdings, Inc. (ONVO) Stock Rating Upgraded by Zacks Investment ResearchOrganovo Holdings, Inc. (ONVO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 15 at 11:32 PM
Critical Review: Organovo Holdings (ONVO) & Its RivalsCritical Review: Organovo Holdings (ONVO) & Its Rivals
www.americanbankingnews.com - October 13 at 2:20 PM
ETFs with exposure to Organovo Holdings, Inc. : October 9, 2017ETFs with exposure to Organovo Holdings, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 8:48 PM
Q3 2018 EPS Estimates for Organovo Holdings, Inc. Decreased by Analyst (ONVO)Q3 2018 EPS Estimates for Organovo Holdings, Inc. Decreased by Analyst (ONVO)
www.americanbankingnews.com - October 9 at 5:56 AM
Organovo Holdings, Inc. (ONVO) Given Average Rating of "Hold" by BrokeragesOrganovo Holdings, Inc. (ONVO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 8 at 9:00 AM
Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q1, 2018 By the Numbers : October 6, 2017Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q1, 2018 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 9:11 AM
Organovo to cut 13% of workforce, announces preliminary revenues - Seeking AlphaOrganovo to cut 13% of workforce, announces preliminary revenues - Seeking Alpha
seekingalpha.com - October 5 at 1:56 PM
Organovo Holdings, Inc. (ONVO) Receives "Buy" Rating from Jefferies Group LLCOrganovo Holdings, Inc. (ONVO) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - September 26 at 8:56 PM
The Competitive Case For Organovo Holdings - Seeking AlphaThe Competitive Case For Organovo Holdings - Seeking Alpha
seekingalpha.com - September 22 at 7:31 AM
Jefferies Group LLC Reiterates "Buy" Rating for Organovo Holdings, Inc. (ONVO)Jefferies Group LLC Reiterates "Buy" Rating for Organovo Holdings, Inc. (ONVO)
www.americanbankingnews.com - September 14 at 7:16 PM
Organovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by AnalystsOrganovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 9:34 AM
BRIEF-Organovo says Keith Murphy submitted resignation as chairman of board‍BRIEF-Organovo says Keith Murphy submitted resignation as chairman of board‍
www.reuters.com - August 29 at 6:23 AM
Global 3D Bioprinting Market Outlook to 2022 - Focus on Technology, Application and Materials - Research and MarketsGlobal 3D Bioprinting Market Outlook to 2022 - Focus on Technology, Application and Materials - Research and Markets
www.businesswire.com - August 26 at 8:01 AM
Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease - NasdaqOrganovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease - Nasdaq
www.nasdaq.com - August 23 at 9:49 AM
Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney DiseaseOrganovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease
finance.yahoo.com - August 23 at 9:49 AM
Organovo Holdings, Inc. (ONVO) Receives Consensus Rating of "Buy" from AnalystsOrganovo Holdings, Inc. (ONVO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 19 at 9:02 AM
Q3 2018 Earnings Forecast for Organovo Holdings, Inc. (NASDAQ:ONVO) Issued By Jefferies GroupQ3 2018 Earnings Forecast for Organovo Holdings, Inc. (NASDAQ:ONVO) Issued By Jefferies Group
www.americanbankingnews.com - August 14 at 7:54 AM
ETFs with exposure to Organovo Holdings, Inc. : August 11, 2017ETFs with exposure to Organovo Holdings, Inc. : August 11, 2017
finance.yahoo.com - August 12 at 6:36 AM
Organovo Holdings, Inc. (ONVO) Announces  Earnings Results, Hits EstimatesOrganovo Holdings, Inc. (ONVO) Announces Earnings Results, Hits Estimates
www.americanbankingnews.com - August 11 at 9:58 PM

SEC Filings

Organovo (NASDAQ:ONVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Organovo (NASDAQ ONVO) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.